MedDataX Logo

Dabigatran Etexilate in Patients With Mechanical Heart Valves

NCT ID: NCT01452347

Last Updated: 2014-08-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

328 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To validate the dosing algorithm for dabigatran etexilate in patients receiving a mechanical heart valve.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Ivabradine on Exercise Capacity After Heart Transplantation

NCT03405831

Cardiac Allograft Vasculopathy Transplanted Heart Complication
UNKNOWN PHASE4

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

NCT03455439

Heart Failure
COMPLETED

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

NCT01839357

Atrial Fibrillation
COMPLETED PHASE3

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

NCT00655538

Coronary Heart Disease
COMPLETED PHASE2

Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)

NCT03975062

Atrial Fibrillation
UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Valve Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dabigatran etexilate

Patient dose dependent on screening CrCl levels and TT

Group Type EXPERIMENTAL

dabigatran etexilate intermediate dose

Intervention Type DRUG

active treatment (medium)

dabigatran etexilate low dose

Intervention Type DRUG

active treatment (low)

dabigatran etexilate high dose

Intervention Type DRUG

active treatment (high)

warfarin

warfarin doses to maintain INR levels

Group Type ACTIVE_COMPARATOR

warfarin 1mg

Intervention Type DRUG

comparator warfarin

warfarin 5mg

Intervention Type DRUG

comparator warfarin

warfarin 3mg

Intervention Type DRUG

comparator warfarin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

warfarin 1mg

comparator warfarin

Intervention Type DRUG

dabigatran etexilate intermediate dose

active treatment (medium)

Intervention Type DRUG

dabigatran etexilate low dose

active treatment (low)

Intervention Type DRUG

warfarin 5mg

comparator warfarin

Intervention Type DRUG

dabigatran etexilate high dose

active treatment (high)

Intervention Type DRUG

warfarin 3mg

comparator warfarin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 18-75
2. Patients who have received a bileaflet mechanical heart valve

Exclusion Criteria

1. Prior valve surgery
2. Uncontrolled hypertension
3. severe renal impairment
4. active liver disease
5. increased risk of bleeding
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1160.113.32003 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1160.113.32007 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

1160.113.32002 Boehringer Ingelheim Investigational Site

Genk, , Belgium

Site Status

1160.113.32005 Boehringer Ingelheim Investigational Site

Ghent, , Belgium

Site Status

1160.113.32001 Boehringer Ingelheim Investigational Site

Leuven, , Belgium

Site Status

1160.113.11002 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1160.113.11006 Boehringer Ingelheim Investigational Site

Winnipeg, Manitoba, Canada

Site Status

1160.113.11001 Boehringer Ingelheim Investigational Site

Saint John, New Brunswick, Canada

Site Status

1160.113.11009 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

Site Status

1160.113.11011 Boehringer Ingelheim Investigational Site

London, Ontario, Canada

Site Status

1160.113.11012 Boehringer Ingelheim Investigational Site

Newmarket, Ontario, Canada

Site Status

1160.113.11007 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1160.113.42002 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1160.113.42005 Boehringer Ingelheim Investigational Site

Hradec Králové, , Czechia

Site Status

1160.113.42003 Boehringer Ingelheim Investigational Site

Olomouc, , Czechia

Site Status

1160.113.42004 Boehringer Ingelheim Investigational Site

Ostrava, , Czechia

Site Status

1160.113.42001 Boehringer Ingelheim Investigational Site

Prague, , Czechia

Site Status

1160.113.45001 Boehringer Ingelheim Investigational Site

Copenhagen, , Denmark

Site Status

1160.113.45002 Boehringer Ingelheim Investigational Site

Odense C, , Denmark

Site Status

1160.113.33004 Boehringer Ingelheim Investigational Site

Bron, , France

Site Status

1160.113.33001 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1160.113.33002 Boehringer Ingelheim Investigational Site

Pessac, , France

Site Status

1160.113.33003 Boehringer Ingelheim Investigational Site

Rennes, , France

Site Status

1160.113.49001 Boehringer Ingelheim Investigational Site

Dresden, , Germany

Site Status

1160.113.49002 Boehringer Ingelheim Investigational Site

Essen, , Germany

Site Status

1160.113.49008 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

1160.113.49004 Boehringer Ingelheim Investigational Site

Freiburg im Breisgau, , Germany

Site Status

1160.113.49003 Boehringer Ingelheim Investigational Site

Heidelberg, , Germany

Site Status

1160.113.49010 Boehringer Ingelheim Investigational Site

Witten, , Germany

Site Status

1160.113.31001 Boehringer Ingelheim Investigational Site

Amsterdam, , Netherlands

Site Status

1160.113.31002 Boehringer Ingelheim Investigational Site

Amsterdam, , Netherlands

Site Status

1160.113.31004 Boehringer Ingelheim Investigational Site

Breda, , Netherlands

Site Status

1160.113.47002 Boehringer Ingelheim Investigational Site

Bergen, , Norway

Site Status

1160.113.47001 Boehringer Ingelheim Investigational Site

Oslo, , Norway

Site Status

1160.113.48004 Boehringer Ingelheim Investigational Site

Gdansk, , Poland

Site Status

1160.113.48003 Boehringer Ingelheim Investigational Site

Warsaw, , Poland

Site Status

1160.113.48001 Boehringer Ingelheim Investigational Site

Wroclaw, , Poland

Site Status

1160.113.46004 Sahlgrenska Universitetssjukhuset

Gothenburg, , Sweden

Site Status

1160.113.46003 Skånes Universitetssjukhus Lund

Lund, , Sweden

Site Status

1160.113.46001 Akademiska Sjukhuset

Uppsala, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Canada Czechia Denmark France Germany Netherlands Norway Poland Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31.

Reference Type DERIVED
PMID: 23991661 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-022685-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1160.113

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents
NCT04703751 UNKNOWN NA
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
NCT03756285 TERMINATED PHASE2
AZD8601 Study in CABG Patients
NCT03370887 COMPLETED PHASE2
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
NCT04630067 COMPLETED PHASE1
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
NCT00353522 COMPLETED PHASE2
The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
NCT00343499 TERMINATED PHASE4
Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
NCT05241431 UNKNOWN PHASE2/PHASE3
A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
NCT04407091 COMPLETED PHASE1
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
NCT04986202 COMPLETED PHASE2/PHASE3
Pharmacokinetic Study to Evaluate Dabigatran Etexilate in Elderly Subjects
NCT05715658 UNKNOWN NA
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375 RECRUITING PHASE2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 RECRUITING PHASE2
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
NCT01877915 COMPLETED PHASE3
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
NCT00516074 COMPLETED PHASE3
Impact of Diabetes on Left Ventricular Remodeling
NCT01052272 COMPLETED PHASE2/PHASE3
Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
NCT04890548 WITHDRAWN PHASE1
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
NCT04475042 UNKNOWN PHASE2
Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
NCT02964949 COMPLETED NA
Pharmacological Reduction of Right Ventricular Enlargement
NCT04345796 COMPLETED PHASE3
PHOspholamban RElated CArdiomyopathy STudy - Intervention
NCT01857856 COMPLETED PHASE3
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
NCT00001534 COMPLETED
Explorative Study of AZD1305 in Atrial Fibrillation Patients
NCT00643448 COMPLETED PHASE2
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
NCT03552575 COMPLETED PHASE3
Laboratory Assessment of the Concentration of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
NCT04684056 UNKNOWN
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
NCT05852704 RECRUITING PHASE3